We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

The Oscillation for Acute Respiratory Distress Syndrome (ARDS) Treated Early (OSCILLATE) Trial (OSCILLATE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01506401
Recruitment Status : Terminated (Enrolment halted by Steering Committee on advice from Data Monitoring Committee.)
First Posted : January 10, 2012
Last Update Posted : August 6, 2015
Canadian Institutes of Health Research (CIHR)
McMaster University
University of Toronto
Information provided by (Responsible Party):
Canadian Critical Care Trials Group

December 14, 2011
January 10, 2012
August 6, 2015
June 2009
September 2012   (Final data collection date for primary outcome measure)
All-cause hospital mortality [ Time Frame: Randomised patients will be ventilated according to their assigned ventilation strategy for up to 60 days, until they die on the ventilator or are successfully (for >24 hours) liberated from mechanical ventilation. ]
all-cause hospital mortality
Same as current
Complete list of historical versions of study NCT01506401 on ClinicalTrials.gov Archive Site
  • Mortality at other time-points [ Time Frame: Duration of hospitalization (ICU discharge, 60 days) ]
    mortality at other time-points (ICU discharge, 60 days)
  • Barotrauma [ Time Frame: ICU discharge or 60 days ]
  • Organ Dysfunction [ Time Frame: Duration of hospitalization or 60 days ]
    Organ Dysfunction
  • Duration of mechanical ventilation [ Time Frame: Duration of hospitalization or 60 days ]
    Duration of mechanical ventilation
  • Duration of ICU & Hospital Stay [ Time Frame: Duration of hospitalization which may exceed 60 days ]
    Duration of ICU & Hospital Stay
  • Quality of Life at 6 months [ Time Frame: 6 months post randomization ]
    Quality of Life at 6 months post randomization
Same as current
Not Provided
Not Provided
The Oscillation for Acute Respiratory Distress Syndrome (ARDS) Treated Early (OSCILLATE) Trial
The Oscillation for ARDS Treated Early (OSCILLATE) Trial
What is the effect of early high frequency oscillation (HFO) versus a lung-protective conventional ventilation (CV) strategy (using HFO only as rescue therapy), on all-cause hospital mortality among patients with severe early acute respiratory distress syndrome (ARDS)?
High frequency oscillation is theoretically ideal for lung protection. Based on a strong physiological rationale, rapidly expanding use internationally, and promising results in early small RCTS, a definitive RCT to establish the impact of HFO versus current conventional ventilation on mortality is needed. We have completed a pilot multicentre RCT in preparation for this trial, with goals of investigating patient recruitment, protocol acceptance, and crossover rates. The pilot study met all objectives including recruitment that exceeded expectations (94 patients), and very good adherence to protocol. Results of the multinational OSCILLATE Trial will establish the impact of HFO versus conventional ventilation on mortality rates among adults with severe ARDS.
Phase 3
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Acute Respiratory Distress Syndrome (ARDS)
  • Device: SensorMedics 3100B High Frequency Oscillatory Ventilator
    High Frequency Oscillation
  • Procedure: Lung Protective Ventilation
    Tidal Volume 6ml/kg; plateau pressure < or = 35cmH20; Prescribed PEEP/FiO2 chart
  • Active Comparator: Conventional Ventilation
    Low tidal volumes, relatively high PEEP.
    Intervention: Procedure: Lung Protective Ventilation
  • Experimental: High Frequency Oscillation
    Open-lung strategy for high frequency oscillation.
    Intervention: Device: SensorMedics 3100B High Frequency Oscillatory Ventilator

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
September 2012
September 2012   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Acute onset of respiratory failure, with fewer than 2 weeks of new pulmonary symptoms;
  • Endotracheal intubation or tracheostomy;
  • Hypoxaemia - defined as a partial pressure of oxygen in arterial blood (PaO2)/fraction of inspired oxygen (FiO2) less than or equal to 200mmHg on FiO2 greater than or equal to 0.5, regardless of positive end expiratory pressure (PEEP)
  • Bilateral alveolar consolidation (airspace disease) seen on frontal chest radiograph

In addition, to qualify for randomization, patients are assessed on the following ventilator settings:

  • Mode: pressure control or volume control or pressure support
  • FiO2 greater than 0.6 (or higher if necessary to keep pulse oximetric saturation [SpO2] greater than 90%)
  • PEEP greater than 10 cm H2O (or greater if necessary to keep SpO2 greater than 90%)
  • Tidal volume 6 ml/kg predicted body weight (PBW)

After at least 30 minutes on these settings, we sample arterial blood to assess oxygenation. If PaO2 is less than or equal to 200 mmHg, the patient qualifies for randomization; if PaO2/FiO2 greater than 200 mmHg, standardized hypoxaemia assessments are repeated at least once daily for the following 72 hours (providing eligibility criteria are still met).

Exclusion Criteria:

  • Remaining duration of mechanical ventilation less than 48 hours, as judged by the attending physician
  • Primary cause of acute respiratory failure judged by attending physician to be circulatory overload due to, for example, congestive heart failure, hyper-resuscitation, or need for dialysis
  • Suspected pulmonary haemorrhage syndrome
  • Lack of commitment to ongoing life support (note that this does not include the presence of a "Do Not Resuscitate" order alone, if there is a commitment to ongoing life support
  • Aged less than 16 years or greater than 85 years
  • Weight less than 35 kg
  • Severe chronic respiratory disease, as indicated by any of:
  • Baseline forced expiratory volume in one second (FEV1) less than 20 ml/kg predicted body weight
  • Pre-existing chronic interstitial lung disease with chronic interstitial infiltration on chest x-ray
  • Documented chronic carbon dioxide (CO2) retention (partial pressure of carbon dioxide in arterial blood [PaCO2] less than 50 mmHg) and/or chronic hypoxaemia(PaO2 less than 55 mmHg on FiO2=0.21)
  • Chronic restrictive, obstructive, neuromuscular, chest wall or pulmonary vascular disease resulting in severe exercise restriction (e.g., unable to climb stairs or perform household duties), secondary polycythaemia, severe pulmonary hypertension (mean pulmonary arterial pressure [PAP] greater than 40 mmHg), or ventilator dependency
  • Morbid obesity - defined as greater than 1 kg/cm body height
  • Underlying pre-existing condition with expected 6-month mortality greater than 50%
  • Neurological conditions with risk of intracranial hypertension (where hypercapnia should be avoided)
  • Neuromuscular disease that will result in prolonged need for mechanical ventilation, including (but not limited to):
  • Guillain Barre syndrome
  • Cervical spinal cord injury
  • Previous randomization in this trial
  • All inclusion criteria present for greater than 73 hours in study intensive care unit (ICU)
  • On HFO at the time of screening
Sexes Eligible for Study: All
16 Years to 85 Years   (Child, Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
Canada,   Chile,   India,   Saudi Arabia,   United States
ISRCTN87124254 ( Registry Identifier: ISRCTN )
Not Provided
Not Provided
Canadian Critical Care Trials Group
Canadian Critical Care Trials Group
  • Canadian Institutes of Health Research (CIHR)
  • McMaster University
  • University of Toronto
Principal Investigator: Niall D Ferguson, MD, MSc University of Toronto
Principal Investigator: Maureen O Meade, MD, MSc McMaster University
Canadian Critical Care Trials Group
September 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP